Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 52 clinical trials
Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer

epirubicin, fluorouracil and cisplatin (or oxaliplatin) are widely used in Europe. However, traditional anthracyclines are more cardiotoxic; and (Pegliposomal Doxorubicin) PLD, as a new liposome dosage form

epirubicin
renal function
fluorouracil
cancer chemotherapy
platelet count
  • 0 views
  • 24 Jan, 2021
  • 1 location
Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases

. Postoperatively, patients receive three 3-weekly courses of chemotherapy with a combination of epirubicin and cyclophosphamide.

metastasis
tamoxifen
lymph node metastases
cyclophosphamide
  • 3 views
  • 24 Jan, 2021
  • 4 locations
Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma

Protocol (Rituximab + Vindesine + Cyclophosphamide + Epirubicin + Prednisone) is the gold therapeutic criteria for patients with NHL, and it is also used as the first-line treatment for patients with DLBCL

hodgkin's disease
ct scan
b-cell lymphoma
prednisone
cyclophosphamide
  • 18 views
  • 21 Jan, 2021
  • 1 location
Dose EScalation Induction of EvERolimus

tumor progression; GeparQuinto study (setting III: non-responders): everolimus was given as salvage treatment in combination with paclitaxel for patients without response to 4 cycles epirubicin

epirubicin
aromatase inhibitor
exemestane
carcinoma
measurable disease
  • 10 views
  • 23 Jan, 2021
  • 14 locations
Trial of Neoadjuvant Docetaxel Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer

fluorouracil /epirubicin/cyclophosphamide (FEC) versus T followed by FEC as neoadjuvant chemotherapy in treating women with triple negative breast cancer (TNBC), and to study the anti-tumor immune effect of

epirubicin
endocrine therapy
triple negative breast cancer
fluorouracil
capecitabine
  • 3 views
  • 26 Jan, 2021
  • 4 locations
Evaluation of Individual Sensitivity to the Gonadotoxicity of Chemotherapy in Young Patients With Breast Cancer

. More than 80% of women of childbearing age, treated for breast cancer with standard protocol of neoadjuvant (4 cycles of 5-fluorouracile - epirubicin- cyclophosphamide (FEC) and 4 cycles of docetaxel

  • 0 views
  • 23 Jan, 2021
  • 1 location
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

) is one most used regimen in second-line in European countries, especially in France. FFCD 0307 trial, a phase III comparing FOLFIRI-ECX (epirubicin-cisplatin-capecitabine) to the reverse sequence

epirubicin
pembrolizumab
serum pregnancy test
gastric cancer
gastric adenocarcinoma
  • 6 views
  • 26 Jan, 2021
  • 6 locations
Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

The study assesses the efficacy of neoadjuvant treatment with pyrotinib and trastuzumab with chemotherapy, mainly pathological complete response (pCR) rates in the breast and axilla. And also assesses side effects, event-free survival (EFS), disease-free survival (DFS), distant disease-free survival (DDFS), and objective response rates (ORR).

  • 0 views
  • 02 Feb, 2021
  • 1 location
Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation

The aim of the study is to perform a French multicenter prospective interventional study in order to assess the feasibility and safety of ovarian hyperstimulation for oocyte / embryo cryopreservation in young women with breast cancer. The oncologic and reproductive benefit / risk ratio will be investigated in the oncology …

immunostimulant
adjuvant chemotherapy
  • 1 views
  • 25 Jan, 2021
  • 42 locations
Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients

This is a multicentric, open-label,non-randomized concurrent control, 1:1 match,non-inferiority trial that assesses the efficacy and safety of neoadjuvant chemotherapy regimen DC-T and EC-T in breast cancer patients.

epirubicin
doxorubicin
invasive breast cancer
core needle biopsy
docetaxel
  • 5 views
  • 23 Jan, 2021
  • 1 location